A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of N6022 in Healthy Subjects.

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of N6022 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs N 6022 (Primary)
  • Indications Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Respiratory tract disorders
  • Focus Adverse reactions; First in man
  • Sponsors N30 Pharma
  • Most Recent Events

    • 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Apr 2011 Planned end date changed from 1 Jan 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 19 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top